针对毛囊淋巴瘤的无化疗方法
Stefano Luminari1,2, Emiliano Barbieri1,3, Maria Elena Nizzoli1,3
1Division of Hematology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
British journal of haematology
|August 30, 2025
概括
新型无化学疗法正在改变毛囊淋巴瘤 (FL) 治疗,为新诊断和复发患者提供替代方案. 这些策略,包括R2和双特异性抗体,即将取代传统化疗,用于高风险病例的CAR T细胞治疗.
科学领域:
- 血液学
- 癌症学
- 临床治疗方法
背景情况:
- 毛囊淋巴瘤 (FL) 的治疗传统上依赖于化疗方案.
- 新兴的新疗法正在转向无化疗方法.
- 这些进展为新诊断的和复发性/耐药性 (RR) FL患者提供了新的希望.
研究的目的:
- 审查毛囊性淋巴瘤的不断发展的治疗环境.
- 突出无化疗策略在FL管理中的作用.
- 讨论新药在FL治疗中的潜在未来应用.
主要方法:
- 对FL的当前临床数据和新兴治疗方案的审查.
- 分析无化疗策略,包括组合疗法和新药.
- 讨论双特异性抗体 (bsAbs) 的定位,布鲁顿氨酸激酶 (BTK) 抑制剂和仿真抗原受体 (CAR) T 细胞疗法.
主要成果:
- 没有化疗的疗程,如Rituximab-Lenalidomide (R2) 在二线设置中得到支持.
- 二特异性抗体 (bsAbs),BTK抑制剂和CAR T细胞疗法是第二次复发后的选择.
- 在未来,bsAbs,特别是莱纳利多米德,可能成为一线或二线选择,可能取代免疫化疗.
结论:
- 毛囊淋巴瘤治疗模式正在向无化疗选择转变.
- 双特异性抗体和CAR T细胞疗法为FL治疗带来了重大进展.
- 需要进行进一步的研究,以制定精确的预后得分,以根据疗效和安全性概况进行最佳的患者分层和治疗选择.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659


